A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Axogen, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 103,886 shares of AXGN stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
103,886
Previous 99,326 4.59%
Holding current value
$1.79 Million
Previous $719,000 102.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$7.52 - $14.69 $34,291 - $66,986
4,560 Added 4.59%
103,886 $1.46 Million
Q2 2024

Jul 19, 2024

BUY
$5.67 - $8.06 $37,229 - $52,921
6,566 Added 7.08%
99,326 $719,000
Q1 2024

Apr 22, 2024

BUY
$6.63 - $10.69 $3,315 - $5,345
500 Added 0.54%
92,760 $748,000
Q4 2023

Jan 16, 2024

BUY
$3.61 - $7.76 $39,710 - $85,360
11,000 Added 13.54%
92,260 $630,000
Q3 2023

Oct 24, 2023

BUY
$4.68 - $9.26 $46,332 - $91,674
9,900 Added 13.87%
81,260 $406,000
Q2 2023

Jul 25, 2023

BUY
$8.5 - $10.38 $157,462 - $192,289
18,525 Added 35.06%
71,360 $651,000
Q1 2023

Apr 14, 2023

BUY
$7.53 - $10.95 $15,880 - $23,093
2,109 Added 4.16%
52,835 $499,000
Q4 2022

Feb 08, 2023

BUY
$9.44 - $13.09 $132,886 - $184,267
14,077 Added 38.41%
50,726 $506,000
Q3 2022

Oct 25, 2022

BUY
$8.14 - $12.25 $84,053 - $126,493
10,326 Added 39.23%
36,649 $437,000
Q2 2022

Aug 12, 2022

SELL
$6.99 - $10.0 $17,475 - $25,000
-2,500 Reduced 8.67%
26,323 $216,000
Q1 2022

May 11, 2022

BUY
$7.26 - $10.7 $68,244 - $100,580
9,400 Added 48.4%
28,823 $229,000
Q4 2021

Feb 08, 2022

BUY
$8.8 - $16.0 $170,922 - $310,768
19,423 New
19,423 $182,000

Others Institutions Holding AXGN

About Axogen, Inc.


  • Ticker AXGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 42,283,700
  • Market Cap $727M
  • Description
  • AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...
More about AXGN
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.